The way HTAs are conducted in Europe is changing. And, if organisations act now to overcome the challenges, they could reap the rewards for years to come.
Recently, pharmaphorum web editor Nicole Raleigh spoke with Herbert Altmann, head of commercialisation and access solutions Europe at PharmaLex, and Casper Paardekooper, partner at Vintura.
The EU’s joint clinical assessment (JCA) initiative has been set up to accelerate patient access to new therapies, but could end up restricting the use of new technologies
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
